Recently, the stock of Divi’s Laboratories, an Indian pharmaceutical business that develops and produces active pharmaceutical ingredients (APIs), has performed well. Its stock price has increased significantly over the past ten years as a result of the company’s solid financial position, capacity for research and development, and emphasis on quality and customer satisfaction.
Investors have been closely monitoring Divi’s Laboratories’ prospects for future expansion. The company is prepared to capitalise on the expanding demand for APIs and other related products as the COVID-19 pandemic highlights the significance of the pharmaceutical sector.
In this piece, we’ll examine Divi’s Laboratories in more detail and discuss its potential.
CLICK HERE TO KNOW MORE:
Hindustan Unilever Ltd Share price target 2023,2025,2030: Can it reach 10000INR by 2025?
DL IN RECENT NEWS
- Shares of Divi’s Laboratories surged by more than 9% due to an increase in exports during the month of March.
DL SHARE PRICE TARGET 2023
| DL SHARE PRICE TARGET 2023 | Maximum Price | Minimum Price |
| April 2023 | ₹3,244.00 | ₹2,495.38 |
| May 2023 | ₹2,703.33 | ₹2,079.49 |
| June 2023 | ₹3,244.00 | ₹2,495.38 |
| July 2023 | ₹3,892.80 | ₹2,994.46 |
| August 2023 | ₹4,282.08 | ₹3,293.91 |
| September 2023 | ₹4,496.18 | ₹3,458.60 |
| October 2023 | ₹4,282.08 | ₹3,293.91 |
| November 2023 | ₹4,710.29 | ₹3,623.30 |
| December 2023 | ₹5,275.52 | ₹4,058.09 |
The data for Divi’s Laboratories Ltd share price target in 2023 shows a mixed but overall positive outlook for the year. April, June, and October are expected to experience moderate growth, with the maximum share price target ranging from ₹3,244.00 to ₹3,244.00. May is expected to be volatile with the possibility of a decline in share price, while July, August, and November are expected to see significant growth, with the maximum share price target ranging from ₹3,892.80 to ₹4,710.29. September is expected to experience continued growth, albeit at a slightly slower pace compared to August. The year is projected to end on a high note in December, with the maximum share price target of ₹5,275.52.
DL SHARE PRICE TARGET 2024
| DL SHARE PRICE TARGET 2024 | Maximum Price | Minimum Price |
| January 2024 | ₹5,553.18 | 1037.03 |
| February 2024 | ₹6,239.53 | ₹5,199.61 |
| March 2024 | ₹6,567.93 | ₹5,339.78 |
| April 2024 | ₹5,970.84 | ₹4,592.96 |
| May 2024 | ₹4,975.70 | ₹3,827.46 |
| June 2024 | ₹5,970.84 | ₹4,592.96 |
| July 2024 | ₹5,075.22 | ₹3,934.28 |
| August 2024 | ₹5,582.74 | ₹4,430.74 |
| September 2024 | ₹5,861.87 | ₹4,509.13 |
| October 2024 | ₹6,896.32 | ₹5,304.86 |
| November 2024 | ₹7,241.14 | ₹5,570.11 |
| December 2024 | ₹7,385.96 | ₹5,681.51 |
Looking at the share price targets for Divi’s Laboratories in 2024, the trend seems to be positive. In January 2024, the maximum share price target is ₹5,553.18, while the minimum is ₹1,037.03, indicating a wide range and potentially significant volatility. However, by February, the maximum and minimum share price targets have narrowed to ₹6,239.53 and ₹5,199.61, respectively, indicating a more stable growth trend. This positive trend continues through March and April, with maximum share price targets of ₹6,567.93 and ₹5,970.84, respectively. However, May 2024 sees a dip in the share price target, with a maximum of ₹4,975.70 and a minimum of ₹3,827.46. The share price target then rebounds in June, with maximum and minimum targets of ₹5,970.84 and ₹4,592.96, respectively. The months of July through September show steady growth, with maximum share price targets increasing each month, from ₹5,075.22 to ₹5,861.87. October 2024 sees a significant increase in maximum share price target to ₹6,896.32, indicating strong growth potential. In November and December 2024, the maximum share price targets are even higher, at ₹7,241.14 and ₹7,385.96, respectively, indicating the potential for significant growth in those months.
CLICK HERE:
SBI SHARE PRICE TARGET 2023,2025, 2030: CAN IT REACH 5000INR BY 2025?
DL SHARE PRICE TARGET 2025
| DL SHARE PRICE TARGET 2025 | Maximum Price | Minimum Price |
| January 2025 | ₹7,533.68 | ₹5,795.14 |
| February 2025 | ₹7,930.19 | ₹6,100.15 |
| March 2025 | ₹8,326.70 | ₹6,405.15 |
| April 2025 | ₹7,434.55 | ₹5,718.89 |
| May 2025 | ₹6,758.68 | ₹5,198.99 |
| June 2025 | ₹7,434.55 | ₹5,718.89 |
| July 2025 | ₹7,080.53 | ₹5,446.56 |
| August 2025 | ₹7,375.55 | ₹5,673.50 |
| September 2025 | ₹7,744.33 | ₹5,957.17 |
| October 2025 | ₹8,208.99 | ₹6,314.60 |
| November 2025 | ₹8,783.61 | ₹6,756.63 |
| December 2025 | ₹8,959.29 | ₹6,891.76 |
According to the given data, Divi’s Laboratories share price target for 2025 is expected to show a positive trend overall, with some fluctuations throughout the year. The maximum share price target for the year is ₹8,959.29 and the minimum share price target is ₹5,198.99. The stock is expected to experience significant growth in February and March, with maximum prices of ₹7,930.19 and ₹8,326.70 respectively. However, there may be some slight dips in share price in April and May, with minimum prices of ₹5,718.89 and ₹5,198.99 respectively. Overall, the trend seems to be upward, with the possibility of new highs in share price in October and November, with maximum prices of ₹8,208.99 and ₹8,783.61 respectively.
DL SHARE PRICE TARGET 2026 TO 2030
| DL SHARE PRICE TARGET BY | Maximum Price | Minimum Price |
| 2026 | ₹6,271.50 | ₹4,390.05 |
| 2027 | ₹5,330.78 | ₹3,731.54 |
| 2028 | ₹9,595.40 | ₹6,716.78 |
| 2029 | ₹19,710.43 | ₹13,797.30 |
| 2030 | ₹21,950.25 | ₹15,365.18 |
Based on the data provided, the share price target for Divi’s Laboratories in 2026 is expected to have a maximum price of ₹6,271.50 and a minimum price of ₹4,390.05. In 2027, the maximum price target is expected to be ₹5,330.78 and the minimum price target is expected to be ₹3,731.54. The share price target for 2028 is expected to have a maximum price of ₹9,595.40 and a minimum price of ₹6,716.78. In 2029, the maximum price target is expected to be ₹19,710.43 and the minimum price target is expected to be ₹13,797.30. For the year 2030, the maximum share price target is expected to be ₹21,950.25 and the minimum price target is expected to be ₹15,365.18.
CLICK HERE:
ADANI PORTS SHARE PRICE TARGET 2023,2025,2030: CAN IT REACH 3000INR?
FINANCIAL STRENGTH OF DIVI’s LABORATORIES LTD ( 2018 TO 2022)
| ANNUAL | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Total Revenue | 9,073.70 | 7,031.96 | 5,584.05 | 5,101.89 | 4,004.93 |
| Total Revenue Growth (%) | 29.04 | 25.93 | 9.45 | 27.39 | -3.24 |
| Total Expenses | 5,390.20 | 4,365.92 | 3,764.59 | 3,246.82 | 2,773.60 |
| Total Expenses Growth (%) | 23.46 | 15.97 | 15.95 | 17.06 | 1.08 |
| Profit after Tax (PAT) | 2,960.45 | 1,984.29 | 1,376.54 | 1,352.74 | 877.01 |
| PAT Growth (%) | 49.19 | 44.15 | 1.76 | 54.24 | -17.30 |
| Operating Profit Margin (%) | 41.12 | 38.26 | 33.84 | 37.57 | 31.67 |
| Net Profit Margin (%) | 33.04 | 28.47 | 25.51 | 27.34 | 22.53 |
| Basic EPS (₹) | 111.52 | 74.75 | 51.85 | 50.96 | 33.04 |
FAQ’s
What is Divi Laboratories Ltd?
Divi Laboratories Ltd is a pharmaceutical company based in India that specializes in the production of active pharmaceutical ingredients (APIs) and intermediates.
What is the revenue growth percentage of Divi Laboratories Ltd in FY 2022?
The revenue growth percentage of Divi Laboratories Ltd in FY 2022 is 29.04%.
What is the net profit margin percentage of Divi Laboratories Ltd in FY 2021?
The net profit margin percentage of Divi Laboratories Ltd in FY 2021 is 28.47%.
What is the basic EPS of Divi Laboratories Ltd in FY 2020?
The basic EPS of Divi Laboratories Ltd in FY 2020 is ₹51.85.
What is the maximum and minimum profit after tax (PAT) of Divi Laboratories Ltd in the last five years?
The maximum PAT of Divi Laboratories Ltd in the last five years is ₹2,960.45 crore in FY 2022, while the minimum PAT is ₹877.01 crore in FY 2018.
What is the operating profit margin percentage of Divi Laboratories Ltd in FY 2021?
The operating profit margin percentage of Divi Laboratories Ltd in FY 2021 is 38.26%.
What is the total revenue of Divi Laboratories Ltd in FY 2019?
The total revenue of Divi Laboratories Ltd in FY 2019 is ₹5,101.89 crore.
What does Divi Laboratories Ltd specialize in producing?
Divi Laboratories Ltd specializes in producing active pharmaceutical ingredients (APIs) and intermediates.
CONCLUSION: DIVI LABORATORIES LTD SHARE PRICE TARGET
According to the financial statement analysis of Divi’s Laboratories Ltd during the previous five years, the business has consistently increased its revenue, PAT, and profit. The company’s overall sales and PAT have been increasing year over year, and operating and net profit margins have been steadily rising, indicating efficient operations. The business has also maintained a solid EPS, which has been continuously increasing over time.
These elements suggest that Divi’s Laboratories Ltd is a good business to invest in over the long term. Before making any investment decisions, it is, however, always advised to do more investigation and study.
